Last reviewed · How we verify

Actinex — Competitive Intelligence Brief

Actinex (MASOPROCOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: masoprocol. Area: Metabolic.

marketed masoprocol Aromatase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Actinex (MASOPROCOL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Actinex TARGET MASOPROCOL marketed masoprocol Aromatase 1992-01-01
Kisqali ribociclib Novartis marketed CDK4/6 inhibitor; aromatase inhibitor Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme 2017-01-01
Aromasin exemestane Pfizer marketed Aromatase Inhibitor [EPC] Aromatase 1999-01-01
Femara letrozole Novartis AG marketed Aromatase Inhibitor [EPC] Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial 1997-07-25
Arimidex anastrozole AstraZeneca marketed Aromatase inhibitor Aromatase enzyme 1995-12-27
ANASTROZOLE ANASTROZOLE marketed Aromatase Inhibitor [EPC] aromatase 1995-01-01
Cytadren AMINOGLUTETHIMIDE Novartis marketed Adrenal Steroid Synthesis Inhibitor Aromatase 1980-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (masoprocol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actinex — Competitive Intelligence Brief. https://druglandscape.com/ci/masoprocol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: